Rua Life Sciences PLC (RUA) fair value: what the stock is really worth
As of Sep 24, 2026: fair value of Rua Life Sciences PLC £0.26, price £0.28, upside -5.5%, quality 44 out of 100. Calculated from audited financials with 26 valuation models and 37 quality factors, updated daily.
Watch Rua Life Sciences PLC for free, get notified when fair value or trend changes. Plus fair value for all 35,000+ stocks, 14 days of Pro free, no card.Watch for freePro now: $1 first month
69 individual criteria per stock, every one traceableSee the method →
Price vs Fair Value
White line = price, green steps = our fair value per fiscal year, dashed = 300-day average. As of Sep 23, 2026.
How to read this chart
60‑month range £0.0875 – £1.65 · fair‑value band £0.1500 – £0.4700 · the £0.2750 price screens above the £0.2600 fair value. Green steps = our fair value per fiscal year (point-in-time, no hindsight). Dashed = 300-day average. As of Sep 23, 2026.
Follow Rua Life Sciences in your weekly email
Every Wednesday you see whether Rua Life Sciences is on track or worth a review, plus price against fair value. Free, up to 3 stocks.
We send you a confirmation link. Unsubscribe with one click.
RUA Life Sciences plc, together with its subsidiaries, develops medical devices in Europe, North America, the Middle East, the Asia Pacific, and Africa. It operates through four segments: Biomaterials, Contract Manufacture, Vascular, and Structural Heart.
Show more
RUA Life Sciences plc, together with its subsidiaries, develops medical devices in Europe, North America, the Middle East, the Asia Pacific, and Africa. It operates through four segments: Biomaterials, Contract Manufacture, Vascular, and Structural Heart. The company acts as the depository of intellectual property and licensing rights to various biostable and implantable polymers, including Elast-Eon and ECSil; and provides sub-contract manufacturing, assembly, packing, and services of medical device, as well as implantable fabric. It also engages in the development and commercialization of bore polymer sealed grafts and soft tissue patches; and development of tri-leaflet polymeric heart valves. The company was formerly known as AorTech International plc and changed its name to RUA Life Sciences plc in June 2020. RUA Life Sciences plc was incorporated in 1996 and is headquartered in Irvine, the United Kingdom.
Stock analysis
Rua Life Sciences PLC (RUA) currently trades at £0.2750, while our model-based Fair Value estimate is £0.2600, implying the stock looks roughly 5.8% fairly valued today.
Show more
Valuation
How firm this estimate is: it rests on 2 models at a data quality of 95/100, which puts the evidence level at low.
Scenario range: £0.1500 (bear) to £0.4700 (bull), the price of £0.2750 sits inside it. Bear and bull are the same models on cautious and optimistic assumptions, a range, not a price target.
Quality & growth
The Quality Score stands at 44/100 (below-average quality), in the Healthcare sector.
Mixed Growth: Revenue is growing, but margins or cash flow do not fully confirm the trend.
Rua Life Sciences PLC reported revenue of 4.5M GBX in FY2026 versus 1.6M GBX in FY2022, a compound +28.7%/yr. Reported net income was −145K GBX in FY2026.
Key figures
Market cap 17.1M GBX · P/S ratio 3.16 · Net margin −3.3% · Return on equity 0.0% · Return on assets (EBIT) −26.5% · Operating margin −8.5% · Revenue (TTM) £4.6M · Revenue growth (YoY) +6.1%.
Competitive moat
Our AI-assisted moat analysis scores the competitive advantage at 42 out of 100 (low confidence).
What moves the price
The share trades about 4% below its 52-week high and 150% above its 52-week low, currently above its 200-day average.
For context, the median of 10 Healthcare peers we cover trades at 5% fair-value upside, at −5%, RUA screens richer than that median.
Fair Value models
Bear £0.1500Fair Value £0.2600Bull £0.4700
Model ⓘEach model values the company its own way (discounted cash flow, earnings, assets, dividends). The fair value above is their evidence-weighted blend, not the output of a single model.Bear ⓘBear = the cautious scenario: the same model computed with conservative anchors (lower growth, margins and valuation multiples). Together with Bull it frames a plausible valuation range, not a price target.BaseBull ⓘBull = the optimistic scenario: the same model computed with favourable anchors (higher growth, margins and valuation multiples). Together with Bear it frames a plausible valuation range, not a price target.Evidence ⓘEvidence = how well-backed THIS model's estimate is for this stock (0–100): how complete and reliable its input data are, and how well the model fits the company. The final Fair Value is an evidence-weighted blend, so better-evidenced models count more. Green ≥70, amber 50–69, grey below 50.
Growth Quality ⓘGrowth is valuable only when reinvestment earns attractive returns (Aswath Damodaran): sustainable growth depends on return on capital, reinvestment and efficiency. Basis: total company revenue over the periods shown on the cards (3Y/5Y/all years), not per share, so a merger can show up as a growth jump; per-share earnings growth is in the value-creation card.50/100
Revenue is growing, but margins or cash flow do not fully confirm the trend.
Revenue growth 1 year
+8.4%
Revenue growth 3 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+27.0%
Revenue growth 5 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+23.9%
Start year 2021 (pandemic). Over 10 years: +21.7% a year
Revenue growth 32 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+4.9%
’15
’16
’17
’18
’19
’20
’21
’22
’23
’24
’25
’26
Profit margin (trend) ⓘOperating margin then vs now, from reported annual statements. A falling margin after a boom year is the classic peak-earnings signal: the growth rate then leans on an inflated base.
−117.5% (2021) → −18.5% (2026)
What shareholders gained per year ⓘWe only publish this rate when it is defensible. Reason: fiscal 2026 is a loss year, no rate is defined from a loss
Price, fair value, quality and upside side by side.
Free, no sign-up
Peer GroupⓘHow this stock ranks against its industry: the green marker is this stock, the band is the typical 25–75% peer range, and the tick is the median.Medical Devices · 365 stocks
Beats the industry median on 4/11 measures
Overall it trails its industry peers.
Valuation
Quality Score46 · Below median
Fair Value upside−6% · Above median
Profitability
Return on equity (TTM)0% · Below median
Return on assets0% · Below median
Net margin (TTM)6% · Above median
Operating margin (TTM)−9% · Below median
Growth and dividend
Revenue growth6% · Above median
Balance sheet
Debt / equity0.02× · Below median
Valuation Multiplesvs Medical Devices median · lower = cheaper
For bloggers, editors and developers: paste this into your site or blog (a “Custom HTML” block in WordPress), it shows the current fair value and links back here. Free, plain HTML, and welcome. Full data streams (CSV/JSON) at /developers.
Cite: Fair Value Calculator (2026). "Rua Life Sciences PLC Fair Value". https://www.fairvalue-calculator.com/stock/RUA
Frequently asked questions
Is Rua Life Sciences PLC (RUA) overvalued or undervalued?
As of Sep 23, 2026, our model estimates a fair value of £0.2600 versus a price of £0.2750, about −5% upside (fairly valued).
What is the fair value of RUA?
Our model-based fair value for Rua Life Sciences PLC is £0.2600 (as of Sep 23, 2026), built from audited fundamentals. The current price: £0.2750.
What is the quality score of RUA?
Rua Life Sciences PLC has a Quality Score of 44/100. It measures business quality (profitability, growth, cash flow, balance-sheet strength, investment discipline, share issuance). Market factors such as price momentum and volatility do not enter the number; they are shown separately in the detail view.
What is the price target for Rua Life Sciences PLC (RUA)?
Our model-based price target is the fair value of £0.2600 (as of Sep 23, 2026) from 2 valuation models. Cautious scenario £0.1500, optimistic scenario £0.4700. It is a calculation from audited fundamentals, not an analyst target.
What is the Rua Life Sciences PLC stock forecast for 2026?
Our models put fair value at £0.2600, about −5% upside versus a price of £0.2750 (fairly valued). Cautious scenario £0.1500, optimistic scenario £0.4700. The calculation is refreshed regularly with new filings.
What is the revenue of Rua Life Sciences PLC (RUA)?
Rua Life Sciences PLC reported trailing-twelve-month revenue of about £4.6M (latest available figure, as of Sep 23, 2026).
What is the intrinsic value of Rua Life Sciences PLC (RUA)?
Intrinsic value and fair value mean the same thing: what the business is worth on its numbers, independent of the share price. For Rua Life Sciences PLC it is £0.2600 per share (as of Sep 23, 2026), against a price of £0.2750. It is the blended result of 2 valuation models (cash flow, earnings, asset, dividend).
Is Rua Life Sciences PLC stock overvalued or undervalued in 2026?
As of Sep 23, 2026, RUA trades above its calculated fair value: price £0.2750, fair value £0.2600, a gap of about −5% (fairly valued). The calculation is refreshed with each new quarterly report, so the verdict can change during the year.
Is fair value the same as the market price of RUA?
No. The price is what the market pays today (£0.2750); the fair value is what the company's own numbers justify (£0.2600). For Rua Life Sciences PLC the two are £0.0150 per share apart. That gap is exactly why we show both numbers side by side.
How much is Rua Life Sciences PLC worth?
The market values Rua Life Sciences PLC at about 17.1M GBX (market capitalisation, as of Sep 23, 2026). Per share that is £0.2750; our models calculate a fair value of £0.2600 per share.
What do the bullish and bearish scenarios say about RUA?
Our models span a range for Rua Life Sciences PLC: cautious scenario £0.1500, base £0.2600, optimistic £0.4700 per share (as of Sep 23, 2026, price £0.2750). The range comes from different growth and margin assumptions, not from analyst opinions.
How solid is the balance sheet of Rua Life Sciences PLC (RUA)?
Balance-sheet figures for Rua Life Sciences PLC (as of Sep 23, 2026): return on equity 0.0%, debt of 0.02 per unit of equity. They feed the Quality Score of 44/100, which measures business quality independently of the share price.
How far is RUA from its 52-week high?
Rua Life Sciences PLC trades at £0.2750, about 4% below its 52-week high of £0.2850 and 150% above the low of £0.1100 (as of Sep 24, 2026). Distance from the high says nothing about value: that is what the fair value of £0.2600 is for.
Which stocks are comparable to Rua Life Sciences PLC?
From the same area (Healthcare) we also value Abbott Laboratories,, Stryker Corporation, Medtronic plc, Boston Scientific Corporation, among others. Each of them has its own fair-value calculation on this site using the same models, so the comparison is like for like.
Is Rua Life Sciences PLC stock attractive at the current price?
The data as of Sep 23, 2026: price £0.2750, calculated fair value £0.2600 (−5%), Quality Score 44/100, from 2 models. Whether that fits your horizon and risk tolerance is your call. We provide the calculation, not investment advice.
How is the fair value of RUA calculated?
We run Rua Life Sciences PLC through 2 models from four families: discounted cash flow, earnings models, asset and balance-sheet models, and dividend models. Every model gets the same audited fundamentals; the result is the weighted average of £0.2600, with the spread shown as a cautious and an optimistic scenario.
Is it still worth investing in stocks now?
The global stock market currently sits 13.0 % above its aggregate fair value. Rua Life Sciences PLC itself currently trades above fair value. An expensive market is no reason to stay out and no reason to buy everything at once: keep a broad savings plan running, buy single stocks only with money you can do without, and hold part of your money liquid while the market is high. The full picture including sectors is on is it worth investing now.
What is the share price of Rua Life Sciences PLC (RUA)?
The closing price on Sep 24, 2026 was £0.2750. Our model-based fair value is £0.2600, about −5% upside (fairly valued). We carry closing prices from our data provider, not a live tick.
What should I pay attention to with Rua Life Sciences PLC right now?
The model range is unusually wide (£0.1500 to £0.4700). The outcome hinges heavily on assumptions, so read the point estimate with caution. The price sits close to our fair value, market and models broadly agree here, little valuation tension. Evidence is limited here (fewer models, shorter history), so the fair value is a rougher estimate than usual.
Key figures of Rua Life Sciences PLC
How large is the market capitalisation of Rua Life Sciences PLC (RUA)?
The market capitalisation of Rua Life Sciences PLC is 17.1M GBX. The stock-market value of the whole company: share price times number of shares. It is what the market asks for the entire business today.
What is the P/S ratio of Rua Life Sciences PLC (RUA)?
The price-to-sales ratio of Rua Life Sciences PLC is 3.16 (last twelve months). Price to sales: market value relative to yearly revenue. Useful when profit is thin or distorted.
What is the net margin of Rua Life Sciences PLC (RUA)?
The net margin of Rua Life Sciences PLC is −3.3% (fiscal year 2026). How much of every unit of revenue ends up as profit. 10% means 10 cents of profit per dollar of sales.
What is the return on equity of Rua Life Sciences PLC (RUA)?
The return on equity (ROE) of Rua Life Sciences PLC is 0.0% (last twelve months). Profit relative to shareholders' equity, how efficiently the company works with its owners' money.
What is the EBIT return on assets of Rua Life Sciences PLC (RUA)?
On an EBIT basis the return on assets of Rua Life Sciences PLC is −26.5% (avg 4y). Operating profit (EBIT) relative to everything the company owns, as a multi-year average. It describes the business model rather than one good or bad year.
What is the operating margin of Rua Life Sciences PLC (RUA)?
The operating margin of Rua Life Sciences PLC is −8.5% (last twelve months). Profit from the core business (before interest and taxes) relative to revenue.
How fast is revenue growing at Rua Life Sciences PLC (RUA)?
Revenue at Rua Life Sciences PLC is growing +6.1% versus a year earlier (3y avg +27.0%). How much revenue grew versus a year earlier (YoY). The 3-year average next to it puts the single year in context.
How much free cash flow does Rua Life Sciences PLC (RUA) generate?
The free cash flow of Rua Life Sciences PLC is −281K GBX (fiscal year 2025). The cash truly left after running and investing in the business, this is what pays dividends and buybacks.
How much net cash does Rua Life Sciences PLC (RUA) hold?
Rua Life Sciences PLC holds more cash than debt, 2.5M GBX net (fiscal year 2025). The company holds more cash than debt, a safety cushion.
Free · no account needed
Watch Rua Life Sciences PLC in the live analysis
One click puts Rua Life Sciences PLC on your watchlist: fair value and trend at a glance, plus comparison, the diversification check and the 35,000+ stock screener. You can also try 14 days of Pro there, no card.
